Lyon – Oral Presentation and Poster Florence Nicolas, Chief Development Officer and co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled « Clinical update of OVX836, a novel Universal Type A influenza vaccine candidate ». Charlotte Primard, Preclinical Project Manager at Osivax, to present a poster entitled « Cross-reactivity of the …
Continuer la lecture « Immunotherapies & Innovation for Infectious Diseases (I4ID) 2023 »